Protein Structure & Design
Chai-1
by Chai Discovery, Inc.
Open-source molecular structure prediction model rivaling AlphaFold 3 for drug discovery
Category
Protein Structure & Design
Founded
2024
Headquarters
San Francisco, CA, USA
Overview
Chai Discovery developed Chai-1, a frontier molecular structure prediction model released in September 2024 that predicts structures of proteins, nucleic acids, small molecules, covalent modifications, and their complexes. Chai-1 achieves accuracy comparable to AlphaFold 3 on the PoseBusters benchmark for protein-ligand docking and the CASP15 multimer benchmark, and is distributed under a permissive license that allows commercial use — a critical advantage over AlphaFold 3's non-commercial research license. Drug discovery teams at biotech companies, academic labs, and computational chemistry groups use Chai-1 for structure-based drug design, hit identification, and modeling protein-ligand interactions as part of virtual screening pipelines. The model supports single-sequence inference (like ESMFold) and MSA-based inference, and accepts user-specified constraints for guided structure prediction. Chai Discovery's core differentiator is combining AlphaFold 3-level accuracy with a commercial-friendly license in an open-weight release. This fills a critical gap in the ecosystem — AlphaFold 3 model weights are restricted to non-commercial use, while Boltz-1 (also fully open) was published two months later. Chai-1's early release and commercial accessibility made it immediately relevant for biotech companies building proprietary drug discovery pipelines on top of open foundation models.
Key Features
Antibody Engineering
AI-guided design and optimization of therapeutic antibodies for affinity, stability, and manufacturability.
Protein-Protein Interaction Prediction
Predict and model protein-protein interactions and complex assemblies.
Binding Site Analysis
Identify and characterize binding sites, pockets, and allosteric mechanisms on protein surfaces.
Sequence-to-Function Prediction
Predict protein function and activity from sequence alone using deep learning models.
Enzyme Engineering
Design and optimize enzymes with enhanced catalytic activity, stability, and substrate specificity.
Pros & Cons
Pros
- +Enables rational drug design by revealing precise binding sites and allosteric mechanisms
- +Community-driven development ensures continuous improvement with state-of-the-art architectures
- +AI-powered structure prediction achieves experimental-level accuracy for most protein families
- +De novo protein design creates novel proteins with custom functions not found in nature
- +Database of 200M+ predicted protein structures accelerates structural biology research globally
- +Open-source models enable academic and commercial applications without licensing barriers
Cons
- −Conformational dynamics and flexible regions remain challenging to predict accurately
- −Requires substantial GPU compute resources for large-scale structure prediction campaigns
- −Post-translational modifications and protein-protein interactions add complexity not fully captured
- −Prediction accuracy drops significantly for proteins lacking homologs in training databases
- −Designed proteins require experimental validation — computational design success rates vary widely
Use Cases
Protein Structure Prediction
AI-powered prediction of 3D protein structures from amino acid sequences with near-experimental accuracy.
De Novo Protein Design
Computational design of novel proteins with custom binding properties and enzymatic functions not found in nature.
Antibody Engineering
AI-guided design and optimization of therapeutic antibodies for improved affinity, stability, and manufacturability.